Cytosorbents (NASDAQ:CTSO) Receives New Coverage from Analysts at StockNews.com

Research analysts at StockNews.com initiated coverage on shares of Cytosorbents (NASDAQ:CTSO) in a research note issued on Wednesday. The firm set a “hold” rating on the medical research company’s stock.

Separately, HC Wainwright reaffirmed a “neutral” rating and issued a $1.00 price target on shares of Cytosorbents in a report on Friday, March 15th.

Cytosorbents Price Performance

Shares of Cytosorbents stock opened at $0.88 on Wednesday. The business has a 50 day simple moving average of $0.94 and a two-hundred day simple moving average of $1.17. Cytosorbents has a 12 month low of $0.78 and a 12 month high of $4.29. The stock has a market capitalization of $47.72 million, a P/E ratio of -1.37 and a beta of 0.58. The company has a debt-to-equity ratio of 0.11, a current ratio of 1.77 and a quick ratio of 1.51.

Cytosorbents (NASDAQ:CTSO) last posted its quarterly earnings results on Thursday, March 14th. The medical research company reported ($0.12) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.02. Cytosorbents had a negative return on equity of 120.24% and a negative net margin of 78.43%. The firm had revenue of $8.67 million during the quarter, compared to analysts’ expectations of $9.29 million. As a group, analysts predict that Cytosorbents will post -0.36 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Key Client Fiduciary Advisors LLC raised its position in Cytosorbents by 188.0% in the first quarter. Key Client Fiduciary Advisors LLC now owns 34,557 shares of the medical research company’s stock valued at $33,000 after purchasing an additional 22,557 shares during the period. Avenir Corp increased its position in shares of Cytosorbents by 12.3% during the 4th quarter. Avenir Corp now owns 3,051,402 shares of the medical research company’s stock worth $3,387,000 after purchasing an additional 334,005 shares during the last quarter. Neuberger Berman Group LLC increased its position in shares of Cytosorbents by 19.9% during the 4th quarter. Neuberger Berman Group LLC now owns 1,801,799 shares of the medical research company’s stock worth $1,997,000 after purchasing an additional 299,103 shares during the last quarter. Skylands Capital LLC increased its position in shares of Cytosorbents by 10.5% during the 4th quarter. Skylands Capital LLC now owns 3,254,213 shares of the medical research company’s stock worth $3,612,000 after purchasing an additional 309,543 shares during the last quarter. Finally, Sargent Investment Group LLC increased its position in shares of Cytosorbents by 4.1% during the 4th quarter. Sargent Investment Group LLC now owns 1,308,747 shares of the medical research company’s stock worth $1,453,000 after purchasing an additional 51,699 shares during the last quarter. 32.87% of the stock is currently owned by hedge funds and other institutional investors.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.